Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2021

View Archived Issues

FDG-PET signal is substantially affected by microglial glucose uptake in neurodegenerative diseases

New spondyloarthritis therapeutic target identified

Elevated plasma CXCL16 levels found in severe COVID-19 patients

LRFN1 gene as a possible cause of autism spectrum disorder

Discovery of broad-spectrum inhibitor of oncogenic BRAF dimerization

Role of de novo mutations in severe male infertility

Hutchison MediPharma patents new CSF1R inhibitors

Chinese researchers disclose new ROS inhibitors

Whole exome sequencing analysis identifies novel genes associated with osteoarthritis

Angiex presents new TM4SF1-targeting PROTACs

Dongguan Hec New Drug Research and Development synthesizes new HBV antivirals

Medshine Discovery describes new compounds for cancer

Alu RNA induces retinal pigment epithelium degeneration in geographic atrophy via the inflammasome

Mitochondrial augmentation: a promising disease-modifying strategy for mitochondrial DNA disorders

NPAS3 identified as a risk gene for autism spectrum disorder

Tango Therapeutics' MTAPnull PRMT5 inhibitor TNG-908 active in multiple xenograft tumor models

HLA fine mapping identifies INPP5A as a risk gene for tuberculosis

Oncodesign and TiumBio collaborate to discover and develop candidates for fibrosis

Mablink and Emergence enter licensing agreement for ADC targeting Nectin-4

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...